FY2025 EPS Estimates for AVITA Medical Boosted by Analyst

AVITA Medical, Inc. (NASDAQ:RCEL - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for shares of AVITA Medical in a note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($0.99) per share for the year, up from their previous estimate of ($1.01). The consensus estimate for AVITA Medical's current full-year earnings is ($0.95) per share.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $22.00 target price on shares of AVITA Medical in a report on Thursday, April 10th.

AVITA Medical Stock Up 0.1%

NASDAQ RCEL traded up $0.01 during trading hours on Wednesday, hitting $6.47. 96,389 shares of the company were exchanged, compared to its average volume of 179,914. The company has a 50 day moving average of $8.70 and a two-hundred day moving average of $10.15. The company has a quick ratio of 2.47, a current ratio of 2.83 and a debt-to-equity ratio of 9.39. AVITA Medical has a 52-week low of $6.17 and a 52-week high of $14.16. The firm has a market cap of $170.93 million, a price-to-earnings ratio of -2.70 and a beta of 1.74.

AVITA Medical (NASDAQ:RCEL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.14). The firm had revenue of $18.51 million during the quarter, compared to analysts' expectations of $33.15 million. AVITA Medical had a negative net margin of 96.26% and a negative return on equity of 337.91%.

Institutional Trading of AVITA Medical

Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in shares of AVITA Medical during the 4th quarter worth about $38,000. CWM LLC grew its holdings in shares of AVITA Medical by 1,099.5% during the 1st quarter. CWM LLC now owns 4,918 shares of the company's stock worth $40,000 after purchasing an additional 4,508 shares during the period. GAMMA Investing LLC grew its holdings in shares of AVITA Medical by 688.9% during the 1st quarter. GAMMA Investing LLC now owns 6,374 shares of the company's stock worth $52,000 after purchasing an additional 5,566 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of AVITA Medical during the 1st quarter worth about $53,000. Finally, Russell Investments Group Ltd. grew its holdings in shares of AVITA Medical by 48.0% during the 4th quarter. Russell Investments Group Ltd. now owns 7,164 shares of the company's stock worth $92,000 after purchasing an additional 2,324 shares during the period. Hedge funds and other institutional investors own 27.66% of the company's stock.

Insider Buying and Selling

In other AVITA Medical news, Director Robert Mcnamara bought 10,000 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average cost of $10.09 per share, for a total transaction of $100,900.00. Following the completion of the purchase, the director now owns 45,749 shares of the company's stock, valued at $461,607.41. This trade represents a 27.97% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.82% of the stock is currently owned by company insiders.

AVITA Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.